Related Experiment Videos
Pentoxifylline inhibits granulocyte and platelet function, including granulocyte priming by platelet activating
D E Hammerschmidt1, D Kotasek, T McCarthy
1Department of Medicine, University of Minnesota Medical School, Minneapolis.
The Journal of Laboratory and Clinical Medicine
|August 1, 1988
Summary
Pentoxifylline demonstrates beneficial effects beyond red blood cell flexibility, significantly inhibiting platelet aggregation and neutrophil functions like chemotaxis and superoxide production. These actions on granulocytes and platelets likely contribute to its overall clinical efficacy in vascular conditions.
Area of Science:
- Pharmacology
- Hematology
- Immunology
Background:
- Pentoxifylline is traditionally associated with improved erythrocyte deformability for arterial insufficiency.
- Previous research suggested this mechanism might not fully explain its clinical benefits.
Purpose of the Study:
- To investigate the effects of pentoxifylline on granulocyte and platelet functions.
- To explore alternative mechanisms beyond erythrocyte effects contributing to pentoxifylline's efficacy.
Main Methods:
- Assessed pentoxifylline's impact on platelet aggregation and adherence to endothelial cells.
- Evaluated inhibition of granulocyte aggregation, adherence, chemotaxis, and superoxide production.
- Investigated pentoxifylline's effect on neutrophil priming by platelet-activating factor.
- Measured intracellular cyclic adenosine monophosphate levels in neutrophils.
Main Results:
- Pentoxifylline inhibited platelet aggregation and thrombin-induced platelet adherence.
- It modestly inhibited granulocyte aggregation and C5a-mediated PMN adherence.
- Significant inhibition of PMN chemotaxis and superoxide production was observed at clinically relevant concentrations.
- Pentoxifylline effectively blocked neutrophil priming by platelet-activating factor.
Conclusions:
- Pentoxifylline exhibits significant inhibitory effects on various platelet and granulocyte functions.
- These cellular effects, particularly on neutrophil priming and chemotaxis, likely contribute to its clinical efficacy.
- The phosphodiesterase inhibitory action may not be the sole explanation for pentoxifylline's broad pharmacological profile.